Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonablative allogeneic hematopoietic stem cell transplantation.

R D Dansey1, R D Baynes

  • 1Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan, USA. dansey@karmanos.org

Current Opinion in Oncology
|January 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idarubicin plus Cytarabine versus Doxorubicin plus Cytarabine in Induction Therapy for Acute Non- Lymphoid Leukaemia: A Randomized Trial.

Leukemia & lymphoma·2016
Same author

Iron deficiency and the measurement of iron status.

Nutrition research reviews·2008
Same author

High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.

Bone marrow transplantation·2002
Same author

Flexible bronchoscopy in the diagnosis of pulmonary infiltrates following autologous peripheral stem cell transplantation for advanced breast cancer.

Bone marrow transplantation·2001
Same author

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future?

Seminars in oncology·2001
Same author

Bone marrow and peripheral blood hematopoietic stem cell transplantation: focus on autografting.

Clinical chemistry·2000
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Nonablative allogeneic stem cell transplantation uses "immunologic space" for engraftment, offering a less toxic alternative to traditional methods. This approach promises broader eligibility and improved quality of life for patients undergoing stem cell therapy.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Recent advancements in nonablative allogeneic stem cell transplantation have significantly expanded knowledge in the field.
  • This method prioritizes creating "immunologic space" for successful engraftment, diverging from traditional "physical space" creation via intensive chemo-radiation.
  • Nonablative transplantation aims to harness potent alloimmune responses for disease eradication while reducing treatment-related toxicity.

Purpose of the Study:

  • To review the current data and underlying principles of nonablative allogeneic stem cell transplantation.
  • To discuss its application in various disease categories, including hematologic and solid malignancies.
  • To evaluate preliminary results and correlative immunologic data associated with this transplantation approach.

Main Methods:

Related Experiment Videos

  • Review of published literature on nonablative allogeneic stem cell transplantation.
  • Analysis of preparative regimens and disease indications.
  • Evaluation of preliminary clinical outcomes and immunologic assessments.

Main Results:

  • Nonablative allogeneic stem cell transplantation enables powerful alloimmune responses for disease eradication.
  • This approach minimizes initial treatment-related morbidity and mortality compared to traditional methods.
  • Preliminary data suggest broader eligibility for curative allogeneic transplantation, reduced costs, and improved quality of life.

Conclusions:

  • Nonablative allogeneic stem cell transplantation represents a critical platform for allogeneic cellular therapy.
  • The approach broadens patient eligibility, potentially reducing healthcare costs and enhancing patient quality of life.
  • Further research and clinical application are warranted to fully realize the potential of this less toxic transplantation strategy.